Business Description
Cisen Pharmaceutical Co Ltd
SIC : 3841
ISIN : CNE100002VG4
Share Class Description:
SHSE:603367: Class ATotal Employee Number:
3,114Compare
Compare
Traded in other countries / regions
603367.China Index Membership
SSE Composite Index IPO Date
2017-09-29Description
Cisen Pharmaceutical Co Ltd is a Chinese pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products. Its portfolio spans generic drugs, active pharmaceutical ingredients, and finished dosage forms, with particular strength in oncology, cardiovascular, anti-infective, and nervous system therapies. The company manufactures a range of formulations including injections, tablets, capsules, and lyophilized powders, and also produces pharmaceutical intermediates and APIs for both internal use and external sale. Cisen serves hospitals, medical institutions, and pharmaceutical distributors across China, with its products primarily marketed domestically through a nationwide sales network. Revenue is generated mainly through the sale of generic pharmaceuticals and APIs, supplemented by research and development services and contract manufacturing. The company operates manufacturing facilities in Shandong Province and invests in R&D to expand its product pipeline and maintain regulatory approvals.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 111.19 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 381.69 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.72 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.3 | |||||
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | -7.9 | |||||
3-Year FCF Growth Rate | 21.8 | |||||
3-Year Book Growth Rate | 5.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.41 | |||||
9-Day RSI | 54.54 | |||||
14-Day RSI | 51.55 | |||||
3-1 Month Momentum % | 7.96 | |||||
6-1 Month Momentum % | -12.53 | |||||
12-1 Month Momentum % | -32.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.53 | |||||
Quick Ratio | 4.07 | |||||
Cash Ratio | 2.86 | |||||
Days Inventory | 146.13 | |||||
Days Sales Outstanding | 70.81 | |||||
Days Payable | 140.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.58 | |||||
Dividend Payout Ratio | 0.34 | |||||
3-Year Dividend Growth Rate | 10.8 | |||||
Forward Dividend Yield % | 2.96 | |||||
5-Year Yield-on-Cost % | 5.3 | |||||
Shareholder Yield % | 2.89 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.04 | |||||
Operating Margin % | 9.75 | |||||
Net Margin % | 13.44 | |||||
EBITDA Margin % | 15.48 | |||||
FCF Margin % | 20.74 | |||||
OCF Margin % | 21.6 | |||||
ROE % | 7.33 | |||||
ROA % | 5.96 | |||||
ROIC % | 8.17 | |||||
3-Year ROIIC % | -5.06 | |||||
ROC (Joel Greenblatt) % | 22.35 | |||||
ROCE % | 8.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.49 | |||||
Forward PE Ratio | 9.15 | |||||
PE Ratio without NRI | 15.68 | |||||
Shiller PE Ratio | 14.05 | |||||
Price-to-Owner-Earnings | 16.51 | |||||
PEG Ratio | 3.16 | |||||
PS Ratio | 1.98 | |||||
PB Ratio | 1.05 | |||||
Price-to-Tangible-Book | 1.08 | |||||
Price-to-Free-Cash-Flow | 13.2 | |||||
Price-to-Operating-Cash-Flow | 12.45 | |||||
EV-to-EBIT | 5.78 | |||||
EV-to-EBITDA | 4.09 | |||||
EV-to-Revenue | 0.89 | |||||
EV-to-FCF | 4.31 | |||||
Price-to-GF-Value | 0.94 | |||||
Price-to-Projected-FCF | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.54 | |||||
Price-to-Graham-Number | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 3.01 | |||||
Earnings Yield (Greenblatt) % | 17.3 | |||||
FCF Yield % | 10.65 | |||||
Forward Rate of Return (Yacktman) % | 15.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cisen Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,398.106 | ||
| EPS (TTM) (Â¥) | 1.008 | ||
| Beta | 0.6994 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.72 | ||
| Volatility % | 28.12 | ||
| 14-Day RSI | 51.55 | ||
| 14-Day ATR (Â¥) | 0.430997 | ||
| 20-Day SMA (Â¥) | 14.4345 | ||
| 12-1 Month Momentum % | -32.5 | ||
| 52-Week Range (Â¥) | 12.13 - 24.85 | ||
| Shares Outstanding (Mil) | 452.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cisen Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cisen Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.216000 Cash Dividend | 2026-09-16 | 13.92 (-1.35%) | ||
| CNY 0.160000 Cash Dividend | 2026-06-03 | 13.92 (-1.63%) | ||
| CNY 0.188000 Cash Dividend | 2025-10-13 | 20.23 (+0.30%) | ||
| CNY 0.220000 Cash Dividend | 2025-06-19 | 14.32 (+0.14%) | ||
| CNY 0.220000 Cash Dividend | 2024-11-22 | 14.77 (+0.14%) |
Show
Entries
Cisen Pharmaceutical Co Ltd Frequently Asked Questions
What is Cisen Pharmaceutical Co Ltd(SHSE:603367)'s stock price today?
The current price of SHSE:603367 is ¥14.60. The 52 week high of SHSE:603367 is ¥24.85 and 52 week low is ¥12.13.
When is next earnings date of Cisen Pharmaceutical Co Ltd(SHSE:603367)?
The next earnings date of Cisen Pharmaceutical Co Ltd(SHSE:603367) is .
Does Cisen Pharmaceutical Co Ltd(SHSE:603367) pay dividends? If so, how much?
The Dividend Yield %  of Cisen Pharmaceutical Co Ltd(SHSE:603367) is 2.58% (As of Today), Highest Dividend Payout Ratio of Cisen Pharmaceutical Co Ltd(SHSE:603367) was 0.72. The lowest was 0.15. And the median was 0.36. The  Forward Dividend Yield % of Cisen Pharmaceutical Co Ltd(SHSE:603367) is 2.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers